|
Tuesday, 30 June 2009 03:00 |
|
Spectrum Pharmaceuticals (Nasdaq: SPPI) has two upcoming dates with regulators in the coming days and months. July 2 Zevalin October 8 Fusilev Bayer Schering (Bayer) markets Zevalin in Europe and abroad - all countries ex. US. Bayer received approval for Zevalin as a first-line consolidation therapy on April 28, 2008. For details, please refer to my recent article here and here. Here are 17 good reasons why Bayer might seriously consider acquiring Spectrum Pharmaceuticals (Nasdaq: SPPI) at some point in the future. Listed below are 17 ongoing clinical trials for Zevalin. Each trial is sorted by its corresponding completion date. Data source: FDA. 2009 August | Phase 2 | Fludarabine Plus Zevalin . . . | September | Phase 2 | Response Study of Zevalin in Patients with DLBCL after 6 cycles of CHOP | December | Phase 3 | Study Comparing Zevalin Regimen with NO further treatment in DLBCL Patients who are in Complete Remission after CHOP-R |
2010 January | Phase 2 | Zevalin in Combination with Z-CHOP in Treating Patients with Stage 2-4 DLBCL | July | Phase 2 | Zevalin + Rituxan Maintenance Sponsor: University of Wisconsin | August | Phase 2 | Autologous Stem Cell Transplant with Zevalin + Busulfan | December | Phase 2 | Chemo followed by Zevalin for Relapsed Mantle Cell Lymphoma Sponsor: Dana-Faber Cancer Institute |
2011 January | Phase 2 | Safety of Zevalin, Sponsor: Bayer Schering |
2012 January | Phase 2 | Zevalin Twice in Aggressive NHL | January | Phase 2 | Safety Study to Evaluate Induction & Consolidation Treatment in Mantle Cell Lymphoma | June | Phase 3 | Zevalin-BEAM for aggressive lymphoma Sponsor: Sheba Medical Center | December | Phase 1 / 2 | Zevalin with Non Myeloablative Allogeneic Stem Cell Transplant in NHL |
2013 April | Phase 2 | Consolidation Treatment with Zevalin after R-CHOP Induction in High Risk Patients According to FLIPI with fNHL |
2014 June | Phase 2 | Zevalin-BEAM with Autologous Stem Cell | August | Phase 2 | Zevalin & Simultaneous Application of BEAM High Dose Chemo | October | Phase 2 | Zevalin First-Line fNHL Sponsor: Charite University, Berlin, Germany |
2016 December | Phase 2 | R-CHOP in fNHL Patients NOT Previously Treated. Consolidation with Zevalin versus Maintenance with Rituxan |
CONCLUSION Though it is NOT possible to conclude that Bayer will acquire SPPI with any certainty, however, it does seem plausible. Contributed by Justin M. Hall Disclosure: Long SPPI
BiomedReports is not paid or compensated to report news and developments about publicly traded companies. Full disclosure can be read at the bottom of / About Us / Section
Add this page to your favorite Social Bookmarking websites
Trackback(0)
 |